Health and Healthcare
GlobeImmune Files For IPO, Cancer & Hepatitis with Great Partnerships
Published:
Last Updated:
GlobeImmune, Inc. is the latest biotech to file for an initial public offering. Financial terms were not disclosed but the first filing is for up to $69 million in common stock. This one has partnerships with Celgene Corporation (NASDAQ: CELG) and Gilead Sciences, Inc. (NASDAQ: GILD) and has five candidates under various stage trials.
Celgene is a 16% owner, Healthcare Ventures is a 14% owner, Morgenthaler is a 14% owner, and Lilly Ventures has more than a 6% stake and that is a $200 million fund tied originally to Eli Lilly & Co. (NYSE: LLY).
Book runners are listed as Wells Fargo Securities and Piper Jaffray, with JMP Securities as a co-manager.
The company description: “We are a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines, which predominately stimulate antibody production. We have four Tarmogen product candidates in five ongoing clinical trials.”
GlobeImmunue’s lead cancer product candidate, GI-4000, is being evaluated in combination with gemcitabine in a fully-enrolled, placebo-controlled Phase 2b trial in resected pancreas cancer. Its lead infectious disease product candidate, GI-5005, has completed a randomized, active-control Phase 2b trial in chronic hepatitis C virus, or HCV, infection.
GlobeImmune has two strategic collaborations, one with Celgene Corporation for all oncology product candidates and one with Gilead Sciences, Inc. for chronic hepatitis B virus, or HBV, infection.
Of course this company is pre-revenue so it has nothing but losses to show to date.
JON C. OGG
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.